Human medicines European public assessment report (EPAR): Bamlanivimab and etesevimab for COVID-19, Status: Withdrawn (during rolling review)
Public-health advice on COVID-19 medicines
ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants: December 2024 update
Summary of opinion: Bridion, 12/12/2024 Positive
Summary of opinion: Rekambys, 12/12/2024 Positive
Procedural advice on paediatric applications
First treatment for peripheral thyrotoxicosis in patients with Allan-Herndon-Dudley syndrome
Orphan designation: tiratricol Treatment of Allan-Herndon-Dudley syndrome, 12/10/2017 Positive
Orphan designation: garadacimab Treatment of hereditary angioedema, 10/12/2021 Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024